AHA op-ed in Medical Economics sets the record straight on 340B program growth and the role of drug companies
“As pharmaceutical companies throw stone after stone at the 340B program, they should beware of their own glass house. Their complaints ring hollow when it is clear that their own actions are driving growth in the program,” says an op-ed in Medical Economics authored by Bharath Krishnamurthy, AHA director of health policy and analytics, and Megha Parikh, AHA associate director of health analytics and policy.
“…Policymakers and the public should reject the fabrications perpetuated by pharmaceutical companies,” Krishnamurthy and Parikh write. “Instead, they should work to protect and support the 340B program and the benefits it affords to countless patients and communities across the country.”
Related News Articles
Headline
The AHA July 14 urged the Health Resources and Services Administration to revise its estimate of the administrative burden associated with the agency’s…
Headline
The AHA today filed a friend-of-the-court brief supporting the Department of Health and Human Services’ motion to dismiss AbbVie’s lawsuit …
Headline
The Health Resources and Services Administration announced that 340B covered entities purchased $100 billion in outpatient drugs under the federal 340B Drug…
Perspective
As we move into the second half of 2026 and Congress returns to work in Washington, D.C., next week, lawmakers face a list of difficult issues that demand…
Headline
The Centers for Medicare & Medicaid Services July 2 issued a proposed rule that would increase Medicare hospital outpatient prospective payment system…
Headline
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week.In a statement…